Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Aliment Pharmacol Ther. 2020 Mar;51(6):629-636. doi: 10.1111/apt.15657. Epub 2020 Feb 12.
Patients with chronic constipation (CC) or with irritable bowel syndrome with constipation are often dissatisfied about their medical therapy, but their condition remains poorly defined.
To evaluate the patients' satisfaction rates and which factors predict favourable outcomes through the aggregate analysis of N-of-1 trials.
Eighty-one outpatients with CC or with irritable bowel syndrome with constipation underwent N-of-1 trials with at least a one-month cycle of effective treatment. Three primary endpoints (satisfaction with therapy, improvement after treatment and an extended satisfaction criterion including both endpoints) were adopted to define satisfaction with therapy. Dyssynergia, resting anal pressure, colonic transit time and somatisation were assessed. The Patient Assessment of Constipation-Symptoms (PAC-SYM) questionnaire and its Modified version (M-PAC-SYM) measured constipation severity. Straining at defecation, stool frequency and form were daily recorded. K statistics for agreement and logistic regression were used at statistical analysis.
Satisfaction with therapy was not achieved by 43% of patients, who had a significantly lower Body Mass Index (BMI) and more severe constipation at baseline. Only the change in constipation severity according to M-PAC-SYM remained significantly associated with satisfaction with therapy (OR = 4.3; P < 0.001) at multivariate analysis.
Satisfaction with therapy is often an unmet need for patients with CC or with irritable bowel syndrome with constipation. Lower BMI and more severe constipation are associated with worse outcome. Changes in M-PAC-SYM reflect satisfaction with therapy. ClinicalTrials.gov no. NCT02813616.
患有慢性便秘(CC)或伴有便秘型肠易激综合征的患者通常对他们的治疗效果不满意,但他们的病情仍未得到明确界定。
通过对 N-of-1 试验的汇总分析,评估患者的满意度和哪些因素可预测良好的结果。
81 名 CC 或伴有便秘型肠易激综合征的门诊患者接受了 N-of-1 试验,其中至少有一个月的有效治疗周期。采用三个主要终点(对治疗的满意度、治疗后改善情况和包括这两个终点的扩展满意度标准)来定义对治疗的满意度。评估了协同失调、静息肛门压力、结肠传输时间和躯体化。采用便秘患者评估症状(PAC-SYM)问卷及其改良版(M-PAC-SYM)来测量便秘严重程度。每天记录排便用力、粪便频率和形状。采用 Kappa 一致性检验和逻辑回归进行统计学分析。
43%的患者对治疗不满意,他们的体重指数(BMI)明显较低,基线时便秘更严重。只有根据 M-PAC-SYM 评估的便秘严重程度的变化与治疗满意度仍有显著相关性(OR=4.3;P<0.001)。
患有 CC 或伴有便秘型肠易激综合征的患者通常对治疗效果不满意。较低的 BMI 和更严重的便秘与更差的治疗结果相关。M-PAC-SYM 的变化反映了对治疗的满意度。临床试验.gov 编号:NCT02813616。